









Markets
/
Stocks
/
nasdaq-tcrt
/

Alaunos Therapeutics Inc

TCRT

2.420USD

-0.080-3.20%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

5.02MMarket Cap

LossP/E TTM



Alaunos Therapeutics Inc

2.420

-0.080-3.20%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

252 / 506

Overall Ranking

411 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.00K.

Overvalued

The company’s latest PE is 0.18, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 252.84K shares, decreasing 36.72% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 20.97K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.64.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.84, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 6.91%.

Score

Industry at a Glance

Previous score

6.84

Change



Financials

5.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.68

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

3.11

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.58

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 7.47, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 0.19, which is -360.04% below the recent high of -0.49 and 1016.68% above the recent low of -1.73.

Score

Industry at a Glance

Previous score

7.47

Change

0.02

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 252/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.89, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.03 and the support level at 1.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.89

Change

-0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.141

Neutral

RSI(14)

51.940

Neutral

STOCH(KDJ)(9,3,3)

80.149

Neutral

ATR(14)

0.179

Low Volatility

CCI(14)

146.132

Buy

Williams %R

20.408

Buy

TRIX(12,20)

-0.195

Sell

StochRSI(14)

64.551

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.378

Buy

MA10

2.326

Buy

MA20

2.191

Buy

MA50

2.591

Sell

MA100

2.996

Sell

MA200

2.464

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 13.09%, representing a quarter-over-quarter decrease of 25.02%. The largest institutional shareholder is The Vanguard, holding a total of 20.97K shares, representing 0.96% of shares outstanding, with 27.04% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Vieser (Jaime W.)

29.93K

+140.07%

Watermill Asset Management

33.33K

Postma (Robert W.)

29.10K

-53.40%

BlackRock Institutional Trust Company, N.A.

21.35K

The Vanguard Group, Inc.

Star Investors

20.97K

Geode Capital Management, L.L.C.

15.61K

+2.59%

UBS Financial Services, Inc.

6.63K

Hogue (Dale Curtis Jr.)

4.44K

+11.05%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.87. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.